| Associated factors | Yes | No | Total | p Value | OR (95%CI) | ||
| N | % | N | % | ||||
| Therapeutic discontinuation | |||||||
| Sex |
|
|
|
|
| 0.025 |
|
| Female | 5 | 9.4 | 48 | 90.6 | 53 |
| Ref |
| Male | 19 | 25.0 | 57 | 75.0 | 76 |
| 3.2 [1.2 - 9.2] |
| Living parent |
|
|
|
|
| 0.027 |
|
| No | 14 | 25.0 | 42 | 75.0 | 56 |
| 3.0 [1.1 - 7.9] |
| Yes | 7 | 10.1 | 62 | 89.9 | 69 |
| Ref |
| Follow-up duration |
|
|
|
|
| 0.013 |
|
| Under 10 years | 19 | 22.4 | 66 | 77.6 | 85 |
| 5.6 [1.3 - 25.4] |
| 10 years and over | 2 | 4.9 | 39 | 95.1 | 41 |
| Ref |
| Transition to second-line | |||||||
| Age group |
|
|
|
|
|
|
|
| 10 years or less | 1 | 2.3 | 42 | 97.7 | 43 | 0.001 | Ref |
|
|
|
|
|
|
|
|
|
| Over 10 years | 27 | 31.4 | 59 | 68.6 | 86 |
| 19.2 [2.5 - 147] |
| Living parents |
|
|
|
|
|
|
|
| Yes | 7 | 12.5 | 49 | 87.5 | 56 | 0.040 | Ref |
| No | 19 | 27.1 | 51 | 72.9 | 70 |
| 2.6 [1.1 - 6.7] |
| Regimen |
|
|
|
|
|
|
|
| ABC + 3TC + LPV/r | 4 | 100.0 | 0 | 0.0 | 4 | 0.038 | Ind |
| TDF + 3TC + LPV/r | 18 | 82.8 | 4 | 18.2 | 22 | 0.019 | 5.7 [1.3 - 45.1] |
| TDF + FTC + LPV/r | 1 | 100.0 | 0 | 0.00 | 1 | 0.235 | Ind |
| AZT + 3TC + LPV/r | 3 | 37.5 | 5 | 62.5 | 8 |
| Ref |
| AZT + 3TC + EFV | 0 | 0.0 | 7 | 100.0 | 7 |
|
|
| AZT + 3TC + NVP | 0 | 0.0 | 36 | 100.0 | 36 |
|
|
| TDF + 3TC + EFV | 0 | 0.0 | 12 | 100 .0 | 12 |
|
|
| TDF + FTC + EFV | 0 | 0.0 | 32 | 100.0 | 32 |
|
|
| ARV treatment duration |
|
|
|
|
| 0.000 |
|
| Under 10 years | 20 | 17.4 | 95 | 82.6 | 115 |
| Ref |
| 10 years and over | 8 | 88.9 | 1 | 11.1 | 9 |
| 38.0 [4.5 - 100] |
| Announcement |
|
|
|
|
|
|
|
| Yes | 23 | 33.3 | 46 | 66.7 | 69 | 0.002 | 4.7 [1.6 - 13.4] |
| No | 5 | 9.6 | 47 | 90.4 | 52 |
| Ref |